Don’t Delay With Delta: Best Practices and Calls to Action in HDV

Download All
In this series of concise, engaging Medical Minutes and podcasts, hear from international experts on the global burden of HDV, risk factors and screening recommendations, new treatment options and current management recommendations, and the evolving therapeutic landscape. Gain patient perspectives to better understand the impact of disease and delays in diagnosis.
person default
Joseph (Patient)
Kosh Agarwal, MD
Maria Buti, MD
person default
Richard H. Davis, PA-C
Graham R. Foster, FRCP, PhD
Robert G. Gish, MD
Paul Y. Kwo, MD
Nancy Reau, MD
Norah Terrault Headshot
Norah Terrault, MD, MPH
Heiner Wedemeyer, MD
Grace LH Wong, MD
Ming-Lung Yu, MD, PhD
person default
Cihan Yurdaydin, MD
person default
Cihan Yurdaydin, MD
Stefan Zeuzem, MD

Medical Minutes

Hear expert insights on the global burden and epidemiology of hepatitis delta virus (HDV) and the challenges associated with accurately diagnosing the population with HDV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 13, 2021 Expired: December 12, 2022

Hear expert insights on whom to test for hepatitis delta virus, how to test, and limitations of current testing options and approaches.

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: January 18, 2022 Expired: January 17, 2023

Hear patient insights on the delay in diagnosis and impact of living with hepatitis delta.

person default Joseph (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: February 3, 2022 Expired: February 2, 2023

Hear expert insights on current treatments for HDV and the importance of developing new agents that are better tolerated and have improved efficacy.

Nancy Reau, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 7, 2022 Expired: March 6, 2023

Hear expert insights on the role in therapy of new and investigational treatments for patients with HDV.

Stefan Zeuzem, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 9, 2022 Expired: March 8, 2023

Hear expert insights on the role of advanced practice providers in the management of hepatitis delta virus infections, including medication monitoring and patient education.

person default Richard H. Davis, PA-C Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 2, 2022 Expired: March 1, 2023

Podcasts

Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. Listen to experts discuss a call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta.

Maria Buti, MD Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 20, 2021 Expired: December 19, 2022

Few treatment options exist for HDV, but many promising investigational agents are on the horizon. Listen to experts discuss what questions still need to be answered to optimize treatment of HDV with current―as well as new and emerging―agents.

Nancy Reau, MD Stefan Zeuzem, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 3, 2022 Expired: March 2, 2023

The hepatitis delta virus (HDV) only coexists in patients chronically infected with hepatitis B virus (HBV). Listen to experts discuss steps to take for monitoring and treating both forms of viral hepatitis.

Heiner Wedemeyer, MD person default Cihan Yurdaydin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 10, 2022 Expired: March 9, 2023

Several emerging agents will soon be available for the treatment of hepatitis delta virus (HDV). Hear experts discuss rational use and combinations of new agents to treat patients with HDV.

Heiner Wedemeyer, MD person default Cihan Yurdaydin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 16, 2022 Expired: March 15, 2023

Listen as 2 experts discuss the importance of increasing healthcare professional and patient awareness of HDV to ensure that at-risk patients receive screening and then treatment and monitoring following a positive test.

Grace LH Wong, MD Ming-Lung Yu, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: May 3, 2022 Expired: May 2, 2023

Your patient tests positive for hepatitis delta virus (HDV). Now what? Listen as 2 experts discuss challenges and opportunities in linking patients with HDV to care.

Kosh Agarwal, MD Graham R. Foster, FRCP, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 30, 2022 Expired: June 29, 2023

Downloadable Slideset

Comprehensive slideset updated regularly to include the latest data and guideline updates for hepatitis delta virus (HDV).

person default Joseph (Patient) Maria Buti, MD person default Richard H. Davis, PA-C Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 25, 2022

ClinicalThought

To link patients with hepatitis delta virus to care, we first must be able to identify them.

person default Cihan Yurdaydin, MD Released: March 8, 2022

Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.

Heiner Wedemeyer, MD Released: March 23, 2022

My thinking about HDV testing recommendations has shifted in recent years. Here’s why.

Norah Terrault Headshot Norah Terrault, MD, MPH Released: May 18, 2022

Our current treatment option for hepatitis delta virus is pegylated interferon alfa, which does not have robust efficacy data and is not always well tolerated—but many novel investigational agents are being studied to provide more efficacious, better tolerated therapies

Paul Y. Kwo, MD Released: August 2, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings